Let The Negotiations Begin: Genentech Rejects Roche’s $44 Billion Bid
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech’s announcement that Roche’s $89 per share bid undervalues the biotech comes as little surprise. But how much is Roche willing to pay?
You may also be interested in...
Roche’s High-Stakes Gambit For Genentech
In a risky attempt to bring Genentech to the negotiating table, Roche appeals directly to shareholders with a lower offer for the flagship biotechnology company.
Roche’s High-Stakes Gambit For Genentech
In a risky attempt to bring Genentech to the negotiating table, Roche appeals directly to shareholders with a lower offer for the flagship biotechnology company.
With Roche Opting Out, ArQule Uncertain On Plans For E2F Oncology Program
Well-capitalized biotech had planned to launch Phase I investigation of E2F molecule in 2009 before Roche’s unexpected decision.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: